Clinical trial
A Phase I, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Potential Activity of HE3286 When Administered Orally to Obese Adult Subjects for 28 Days
NCT00555451 is registered in ClinicalTrials.gov with Harbor Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Potential Activity of HE3286 When Administered Orally to Obese Adult Subjects for 28 Days
- Lead sponsor
- Harbor Therapeutics
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 31, 2007
- Completion date
- September 30, 2009
- Enrollment
- 66 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.